Purpose: To compare subbasal corneal nerve and keratocyte density and endothelial characteristics of ocular hypertensive patients treated with medications or observation.
G
overnmental drug approval processes and extensive worldwide clinical experience among millions of patients with glaucoma have established the clinical use of various intraocular pressure-lowering medications. Clinicians have been concerned about the effects of some of these topical medications and their preservatives on ocular surface function and integrity, and some have associated the use of these drugs with local allergic reactions, chronic inflammation of the conjunctiva, 1,2 tear film abnormalities, [3] [4] [5] or corneal epitheliopathy. 6, 7 Symptoms from these adverse effects may be relatively common. 8 Toxicity to deeper corneal layers is not normally considered to be a risk, 9 but several reports, including animal 10 and human studies, 11, 12 suggest concern, at least in specific clinical settings such as preexisting corneal abnormalities.
The Ocular Hypertension Treatment Study (OHTS) provides an ideal opportunity to study the effects of chronic topical glaucoma medication on the human cornea. The OHTS is a prospective, randomized, multicenter study to assess the risk of progression to primary open-angle glaucoma in ocular hypertensive participants treated with either medications or observation. 13 In the current ancillary study to the OHTS, we examined corneas of patients with specular microscopy annually and with confocal microscopy once, 6 to 9 years after enrollment. Densities of keratocytes, subbasal nerves, and endothelium were compared between patients who were treated with ocular hypotensive medications and those who were not treated.
MATERIALS AND METHODS

Patients
The protocols of both the OHTS and the ancillary specular microscopy and confocal microscopy studies were approved by the Mayo Clinic Institutional Review Board and the OHTS Data Safety and Monitoring Committee. Study participants were recruited for the OHTS at Mayo Clinic between April 1994 and January 1996 and randomized to either medical treatment or observation. Patients were eligible if they had normal-appearing optic discs, normal visual fields, and intraocular pressures between 24 and 32 mm Hg in 1 eye and between 21 and 32 mm Hg in the contralateral eye. 13 Fiftyfive patients at Mayo Clinic gave written informed consent to participate in the OHTS and this ancillary study. These studies conformed to the tenets of the Declaration of Helsinki.
Participants in the medication group were treated bilaterally with topical medications commercially available in the United States to achieve a target IOP of 24 mm Hg or less and a minimum 20% reduction in IOP from the average of the qualifying IOP and IOP at the baseline randomization visit. The minimum target pressure was 18 mm Hg. Topical medication was changed or new medications were added at the discretion of the OHTS investigator (D.C.H.) until both of these goals were met or the participant was receiving maximumtolerated topical medical therapy.
Endothelial Morphometry
Images of the central corneal endothelial were recorded by contact specular microscopy (SP-580; Keeler Instruments, Broomall, PA) at the time of enrollment and annually for 6 years. The apices of 100 contiguous endothelial cells were digitized manually (Bambi 6.1; Bio-Optics, Arlington, MA) by 1 investigator (E.J.W.) and endothelial cell density, coefficient of variation, and percent hexagonal cells were calculated.
14 These variables were compared between groups and to the same variables from a control group, consisting of agematched normal subjects without a history of anterior segment eye disease or surgery, diabetes, or contact lens wear, using the same methods previously.
Confocal Microscopy
Corneas of each patient were examined with a confocal microscope (Tandem Scanning Confocal Microscope, Reston, VA) as described by Patel et al. 15 Each cornea was scanned 3 to 6 times through its entire depth. The video camera of the confocal microscope was set in an automatic-gain mode to optimize image brightness when assessing cell density and in a manual-gain mode to estimate brightness of backscattered light. At least 1 scan per cornea was recorded in each mode.
Subbasal Nerve Density
Subbasal nerve fiber bundles form a plexus just anterior to the Bowman membrane 16 and are typically visible through several frames of a confocal examination (Fig. 1) . In all frames that contained subbasal nerves, 1 investigator (K.H.B.) using a custom program 17 traced the paths of all main nerves and their branches greater than 50 mm through multiple frames if necessary. The program calculated the total number and length of main nerves and their branches as well as the mean angles of main nerves in this layer. Nerve number was the number of nerves and branches in a frame of a confocal scan, expressed as nerves per frame. Nerve density was expressed as the total length of all main nerves and their branches divided by the area of stroma represented by the image (0.191 mm 2 for all scans), expressed as micrometers per square millimeter. The nerve number and density and mean nerve angle for each cornea was the mean of the values of the individual scans. The observer was masked to the name and randomization status of the patients. Nerve fiber density measurements included data from all analyzable scans of all eyes.
Keratocyte Density
Keratocyte density was determined using a manual method of counting images of cell nuclei in a predefined area of confocal images. 18 Measurements were obtained from 1 representative scan from each eye. Two nonblurred frames were selected from each of 5 layers of the stroma: the anterior 10%, 11% to 33%, 34% to 66%, 67% to 90%, and posterior 10% of stromal depth, based on the frames that contained the anteriormost keratocytes and the endothelium. One observer (C.B.N.) identified and marked bright objects that resembled keratocyte nuclei inside a predefined rectangular field drawn within each frame. Objects that touched the lower or left boundaries of the field were included, but those that touched the upper or right boundaries were excluded. Cell density, expressed as cells per cubic millimeter, was the number of objects in the rectangular area divided by the product of the area of the field (0.109 mm 2 ) and the optical depth of field (11.9 mm). The mean cell density of each stroma was the mean density of the 10 frames weighted by the distance between frames. The observer was masked to the name of the patient, the randomization status, and the depth of the frame in the stroma. Keratocyte density was determined from 1 representative scan of each eye.
Backscattered Light From the Stroma
Because increased backscattered light can increase image intensity and decrease the ability to discern nerves and cells in a confocal scan, we attempted to quantify this variable. The brightness of backscattered light from the stroma was determined from the average intensity of each frame in scans recorded with the video camera in manual-gain mode. Average intensities were calculated by using a custom program that calculated the mean brightness of the central 0.109 mm 2 of each frame. Mean brightnesses were adjusted for variations in sensitivity of the confocal microscope (brightness of the light source and sensitivity of the camera) using the mean brightness of images of a fluorescent glass standard scanned immediately before scanning each patient. 19 
Statistical Analysis
Mean nerve number, density, angle, and keratocyte density were calculated for each eye by averaging the values obtained from individual scans. These values and endothelial morphometric variables for both eyes were averaged for each patient. Descriptive statistics were calculated for each variable and each randomization group. Variables were compared between the medication and observation groups by using t tests or a rank sum test, depending on whether data were normally distributed. Endothelial variables were compared at baseline and at 72 months. Statistical tests were adjusted for 2 comparisons by using the Bonferroni technique. The rate of endothelial cell loss for each participant expressed as a percent per year was assumed to be equal to 100 3 e k 3 1 year , where k is the slope of the line fitted by linear regression to the natural logs of all mean densities versus time between baseline and 6 years. The percent loss per year was calculated for each subject and was compared between groups by using a rank sum test.
RESULTS
Patients
Of the 55 participants enrolled in the OHTS at our center, 27 were randomized to the medication group and 28 were randomized to the observation group. Follow-up data were not available for 1 participant in the observation group who moved and transferred care to another study center. There were no significant differences in the baseline demographics between the randomization groups. Mean age of the observation group at enrollment was 59 6 9 years compared with 57 6 11 years for the medication group (P = 0.44). The proportion of male patients was 44% for the observation group and 56% for the medication group (P = 0.41). Before enrollment in the OHTS, 7 participants in the medication group used b-adrenergic antagonist eye drops for a mean of 66 months (range, 8-218 months), and 4 participants in the observation group used these drops for a mean of 57 months (range, 34-74 months). No other participants had used intraocular pressure-lowering medications before enrollment in the OHTS, and no participants had used glaucoma medications other than b-adrenergic antagonists. Medications used after randomization included apraclonidine 0.5%, betaxolol 0.25%, brimonidine 0.15% and 0.2%, brinzolamide 1%, dorzolamide 2%, latanoprost 0.005%, pilocarpine 0.5% and 1%, timolol 0.5%, dorzolamide 2%/timolol 0.5% combination, and unoprostone 0.15%. Both eyes of each participant were treated with the same medications generally, but this was not universal.
Endothelial Morphometry
In addition to the 1 observation participant who moved to another study center, 6-year endothelial data were not available for 2 patients, 1 in each group, who did not reconsent after 5 years. Data were not recorded at 6 years for 1 observation group participant and at 2 and 3 years for 1 medication group participant. Four other patients in the observation group began medication during the study because of conversion to glaucoma. Subsequent endothelial data from these patients were excluded from analysis. Thus, the available sample for endothelial morphometry at 6 years was 26 in the medication group and 21 in the observation group.
At baseline or after 6 years of follow-up, the endothelial cell density, percent hexagonal cells, and coefficient of variation did not differ significantly between the observation and medication groups (Table 1; Fig. 2) . Also, no significant differences in these parameters occurred at any other time interval. This sample size provides adequate statistical power (a = 0.025, b = 0.20) to detect a difference at 72 months of 250 cells/mm 2 for endothelial cell density, 0.06 for coefficient of variation, and 10% for percent hexagonal cells. Except for coefficient of variation, the groups also did not differ significantly from a historical group of 55 age-matched controls (Table 1) . After excluding the 4 observation participants who started medication within the first 6 years of follow-up, the annual rate of corneal endothelial cell loss was similar at 0.85% in the observation group and 0.68% in the medication group (P = 0.70). 
Confocal Microscopy
Thirty-eight eligible patients, 19 in each randomization group, consented to confocal microscopy and were evaluated 92 6 6 months (range, 78-108 months) from OHTS enrollment. The remaining 16 patients declined to participate in this ancillary study or had bilateral cataract surgery. In the instance of unilateral cataract surgery, the contralateral eye remained in the study. Before confocal microscopy, 9 of the 19 subjects in the observation group were started on medication (observation-to-medication group), because they progressed to glaucoma during the first 6 years of the study (n = 4) or elected to start therapy when the OHTS observation group was opened to treatment at the end of 6 years.
A total of 312 confocal scans were obtained. Fifty-five scans (18%) were deemed not analyzable for nerve analysis, usually because of patient movement. The proportion of eyes with at least 1 unanalyzable scan was 44% in the medication group, 40% in the observation group, and 53% in the observation-to-medication group (P = 0.72). The median number of analyzable scans was 4 per eye (range, 0-6) in each of the 3 study groups. All participants had at least 1 analyzable scan for nerves, but 1 participant in the treatment group had no analyzable scans for keratocyte density analysis.
Subbasal Nerve Density
The number and density of central, subbasal, and corneal nerves were lower in the medication group than in the observation group (P = 0.02 for nerve number; P = 0.007 for nerve density; Table 2 ). The mean nerve angle was not statistically different between the 2 groups (P = 0.10). The number and density of nerves in the observation-to-medication group were intermediate to the other groups.
Keratocyte Density
The keratocyte density averaged over the full thickness of the cornea did not differ significantly between the observation and medication groups (Table 2) . Likewise, the density of cells in the anterior 10% of the stroma, where the keratocytes tend to be most dense, was also similar. The fullthickness stromal keratocyte densities in the study groups were similar to the value (20,522 6 2981 cells/mm 2 ) of a normal group of subjects studied using identical methods. 18 
Backscattered Light From the Stroma
The light intensity for confocal images was similar among the groups (Fig. 3) . This similarity was consistent at all depths of the cornea.
DISCUSSION
The stromal keratocyte and endothelial cell densities of corneas of study participants on chronic, topical glaucoma medications are not different from those of control patients. These results indicate that these medications may be used without damage to these cells in most situations. In light of the extensive clinical experience with these medications, our findings are not surprising. Previous studies of various glaucoma drops in humans also have not found a deleterious effect on endothelial cell density, 9,20-22 corneal deswelling rates, 12, 21 or fluorescein permeability. 23 In contrast, some animal studies have suggested that the ultrastructure of the endothelium changes after chronic use of glaucoma medications. 10 Also, Konowal et al. 11 reported irreversible corneal decompensation after initiating topical 12 and the potential for a delayed deswelling rate in a subset of patients. 21 Our study found no adverse trend in the density or morphology of endothelial cells in patients on glaucoma medication. The rate of endothelial cell loss in the 2 randomization groups was similar, and the 0.68% decrease per year among medicated patients was similar to the 0.6% found during 10 years in normal corneas. 24 In contrast to the stability of keratocytes and endothelium, we found a significant decrease in the density of subbasal nerve fiber bundles visible with confocal microscopy in the treated group. This effect on the subbasal nerves is somewhat unexpected. Several questions must be answered before we understand the implications of our findings.
First, are functional changes linked to the decrease in nerve fiber bundles? Neurotrophic keratitis, which may result from nerve loss in diseases such as herpes zoster ophthalmicus, is associated with decreased corneal sensation, punctate keratopathy, tear film abnormalities, and, in the most severe cases, persistent epithelial defects and ulceration. [25] [26] [27] To our knowledge, no large, rigorous studies have established a consistent link between clinical neurotrophic disease and glaucoma therapy. However, several cases of corneal insensitivity, sometimes in conjunction with profound ocular surface abnormalities, were documented in patients who used topical b-adrenergic antagonists. [28] [29] [30] [31] Commercial preparations of prostaglandin analogs may also transiently decrease corneal sensation. 32 Other case series and case reports have implicated b-adrenergic antagonists, prostaglandin analogs, and preservatives as causing symptomatic ocular surface changes such as punctate corneal epitheliopathy, 2, 5, 7, 8, 33 medically resistant herpetic keratitis, 6, 34 and ocular discomfort. 8 Other researchers have reported less symptomatic findings such as tear film instability, 3, 4, 35 disruption of the epithelial barrier function, 33, 36 and chronic inflammatory infiltration 37, 38 or expression of inflammatory markers 39 in the conjunctiva. These effects, as well as impaired epithelial wound healing [40] [41] [42] and ultrastructural surface abnormalities, 1, 42, 43 have been confirmed in animal models and in vitro. 37, 44 Many of these adverse effects have been linked to, but not exclusively attributed to, the preservative benzalkonium chloride. 1, 8, 33, 36, 37, 39, 40 Second, are the decreased numbers of subbasal nerves associated with other anatomic changes? Investigators studying the neurotrophic cornea have described decreased epithelial cell mitotic activity, 45 thinning of the epithelium, and a decrease in the number of epithelial cell layers. 46 Data from the same Mayo OHTS cohort showed a decrease in mean corneal thickness in the medication group, partially attributed to a thinner epithelium. 47 Epithelial thinning was probably the result of the medication rather than an abnormality in the observation group, whose epithelial thickness was not different from that of normal subjects 18 examined with identical techniques. We propose as a hypothesis that the epithelial thinning results from the decreased nerve density. Such an effect, in conjunction with the epitheliopathy described by others, would be consistent with a subclinical neurotrophic keratitis in a proportion of these chronically treated ocular hypertensive patients.
Third, how extensive must the loss of nerves be to cause the clinical neurotrophic keratitis seen in the few reports of eyes subjected to b-adrenergic antagonist therapy? Large limbal incisions that interrupt up to one half of the limbal nerve branches during intracapsular cataract extraction cause few clinical problems. Similarly, patients with previously healthy ocular surfaces who undergo penetrating keratoplasty can recreate a relatively healthy epithelial and tear film layer despite profound sensory loss. It should be noted, however, that keratoplasty does not affect limbal and stem cell tissue.
Finally, what caused nerve loss in patients on medication? Previous studies described b-adrenergic antagonists as a cause of decreased corneal sensation. [28] [29] [30] [31] Our sample size is too small to perform any subgroup analysis, which prevents us from implicating specific medications or preservatives.
Despite our prospective, randomized design, this ancillary study has limitations. In addition to the study sample confined to 1 institution, the observation group evaluated with confocal microscopy is small, because of conversion of participants to medication, bilateral cataract surgery, and failure to consent to the ancillary study. Also, confocal microscopy at the beginning of the study, rather than only at the end, could have identified potential baseline differences between the groups of participants. Most importantly, the simultaneous and sequential use of medications in the study group presents 1 uncontrollable variable.
Keratocyte densities and variability in the data derived from confocal images with the current technique have been validated in our laboratory by comparison with densities determined by histologic methods. 18 We have not similarly validated our nerve fiber bundle densities, nor have we evaluated the variability of an observer in estimating nerve densities from confocal images frames that are counted only once in this study. We do attempt to compensate for this limitation by evaluating multiple confocal scans of each eye. However, in our experience, the quality of the confocal scan, which may be degraded by patient movement or background image intensity, can affect the ability to identify subbasal nerves and produce falsely low estimates of nerve density. Eighteen percent of the scans were graded as unreadable because of patient movement and 2% were deemed to be highquality scans with no visible nerves. However, the proportion of patients with at least 1 confocal scan that was not analyzable was similar among the groups (P = 0.72). Backscattered light and image intensity also appeared similar among the study groups, so a difference in image quality cannot explain the difference measured in subbasal nerves.
Regional variation in subbasal nerve density does occur. 48 The orientation of the nerve fiber bundles may also be altered as a result of surgery or disease. 49 Our measurements, which are generally within 1 mm of the center of the cornea, may not be representative of the entire cornea, and alterations in the distribution or orientation of nerve fibers could affect our nerve density data.
Further clarification of the relationship between glaucoma medication and decreased corneal nerve density should focus on identifying the specific causative agents and the interactions between nerve density, epithelial thickness, and corneal sensation. This endeavor would require larger cohorts of patients and the use of devices that can reliably detect small differences in corneal sensitivity and structure. Histologic confirmation of nerve density measurements derived from confocal microscopy is also appropriate.
